Kathleen Bailey, MS, NP, PhD

As a Nurse Practitioner, Kathleen provided direct patient care for 5 years and also participated in clinical research and as a Director of medical staff in HIV and infectious disease private practice settings. 

How Liam Blaney lives life to the fullest

Why did Liam Blaney, quality data metrics analyst at Labcorp, jump out of an airplane? To raise money for a cause near and dear to his heart.

How Fraser found his wings at Labcorp

As a kid, Fraser loved going to air shows with his father. This paved a direct line for his career aspirations, and he attended flight school at Elon Aviation in Burlington, North Carolina. While he never thought his career would take off in a way that landed him at Labcorp, he is glad it did.

Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies

This study looks into the genetic landscape of 24,639 clinical myeloid samples assessed by the IntelliGEN® Myeloid Panel showing the utility of comprehensive genomic testing to guide clinical decisions. In recent years guidelines for myeloid diseases including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN) have been updated to incorporate genomic mutation status in an increasing number of genes. We observed an average of 1.95 mutations per patient with 48.7% having mutations in genes used in diagnostic criteria while 61.6% of MDS patients had prognostic mutations. In total, we detected over 48,000 variants across the panel of 50 genes, shedding light on the intricate genetic tapestry of myeloid disease observed in real-world samples. This expansive retrospective study underscores the power of NGS testing in guiding clinical decisions within routine care and illuminates the mutational landscape within the myeloid patient community.